Related references
Note: Only part of the references are listed.THE ASPIRE TRIAL: TMC435 IN TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE-1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGIFN/RBV TREATMENT
S. Zeuzem et al.
JOURNAL OF HEPATOLOGY (2011)
QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS
A. Lok et al.
JOURNAL OF HEPATOLOGY (2011)
BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION
J. -P. Bronowicki et al.
JOURNAL OF HEPATOLOGY (2011)
Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice
Eiji Ohara et al.
JOURNAL OF HEPATOLOGY (2011)
Influence of HCV Genotype 1 Subtypes on the Virus Response to PEG Interferon Alpha-2a Plus Ribavirin Therapy
F. Nicot et al.
JOURNAL OF MEDICAL VIROLOGY (2011)
A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt
William Sievert et al.
LIVER INTERNATIONAL (2011)
The global health burden of hepatitis C virus infection
Francesco Negro et al.
LIVER INTERNATIONAL (2011)
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
Markus Cornberg et al.
LIVER INTERNATIONAL (2011)
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Retreatment of HCV Infection
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System
Robert A. Fridell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
Alexander J. Thompson et al.
GASTROENTEROLOGY (2010)
IDENTIFICATION AND PRECLINICAL PROFILE OF THE NOVEL HCV N53 PROTEASE INHIBITOR BMS-650032
F. McPhee
JOURNAL OF HEPATOLOGY (2010)
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
Edward J. Gane et al.
LANCET (2010)
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Min Gao et al.
NATURE (2010)
Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding
Keith P. Romano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-α2b A Randomized Trial
Donald M. Jensen et al.
ANNALS OF INTERNAL MEDICINE (2009)
New Therapies for Hepatitis C Virus Infection
Vincent Soriano et al.
CLINICAL INFECTIOUS DISEASES (2009)
Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy
Thierry Poynard et al.
GASTROENTEROLOGY (2009)
Diagnosis, Management, and Treatment of Hepatitis C: An Update
Marc G. Ghany et al.
HEPATOLOGY (2009)
Characterization of Resistance to the Protease Inhibitor Boceprevir in Hepatitis C Virus-Infected Patients
Simone Susser et al.
HEPATOLOGY (2009)
Influence of the HCV Subtype on the Virological Response to Pegylated Interferon and Ribavirin Therapy
Florence Legrand-Abravanel et al.
JOURNAL OF MEDICAL VIROLOGY (2009)
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir
Christoph Sarrazin et al.
GASTROENTEROLOGY (2007)
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002
Gregory L. Armstrong et al.
ANNALS OF INTERNAL MEDICINE (2006)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
MW Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
MP Manns et al.
LANCET (2001)
Share Paper
